Quick Answer
Niagen Bioscience, Inc. reported Stockholders Equity of $76.53 million for fiscal year 2025.
Niagen Bioscience, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $76.53M | +66.0% |
| 2024 | $46.09M | +62.0% |
| 2023 | $28.46M | -0.8% |
| 2022 | $28.67M | -9.6% |
| 2021 | $31.73M | +93.2% |
| 2020 | $16.42M | -19.7% |
| 2019 | $20.45M | -24.8% |
| 2018 | $27.18M | -49.5% |
| 2017 | $53.83M | +439.7% |
| 2016 | $9.97M | +89.1% |
| 2015 | $5.27M | +31.9% |
| 2014 | $4.00M | -29.4% |
| 2013 | $5.67M | +41.9% |
| 2012 | $3.99M | +55.9% |
| 2011 | $2.56M | -48.1% |
| 2010 | $4.94M | +371.3% |
| 2009 | $1.05M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $70.68M | +105.6% | +10.1% |
| June 30, 2025 | $64.19M | +109.0% | +16.0% |
| March 31, 2025 | $55.34M | +91.2% | +20.1% |
| December 31, 2024 | $46.09M | +62.0% | +34.1% |
| September 30, 2024 | $34.37M | +25.9% | +11.9% |
| June 30, 2024 | $30.72M | +13.1% | +6.1% |
| March 31, 2024 | $28.95M | +3.3% | +1.7% |
| December 31, 2023 | $28.46M | -0.8% | +4.2% |
- Niagen Bioscience, Inc. showed an increase of +66.0% in Stockholders Equity compared to the prior fiscal year.
- Over the 2009–2025 period, Niagen Bioscience, Inc.’s stockholders equity has grown by 7206.6% (from $1.05 million to $76.53 million).
- The most recent figure is from Niagen Bioscience, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: